Signaling pathway switch in breast cancer

Cancer Cell International

Daniel Birnbaum¹  Max Chaffanet¹  Arnaud Guille¹ 

[1] Centre de Recherche en Cancérologie de Marseille, Oncologie Moléculaire, “Equipe labellisée Ligue Contre le Cancer”, UMR1068 Inserm, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille Université, 27 bd. Leï Roure, BP 30059, Marseille 13273, France

关键词: Kinases;    Cell cycle;    Signaling pathways;    Breast cancer;    Next generation sequencing;   

Others  :  793461
DOI  :  10.1186/1475-2867-13-66

 received in 2013-05-14, accepted in 2013-06-20,  发布年份 2013

【 摘 要 】

Next generation sequencing studies have drawn the general landscape of breast cancers and identified hundreds of new, actual therapeutic targets. Two major signaling pathways seem to be altered in a vast proportion of breast cancers. The PI3 kinase/AKT pathway is activated and the JUN/MAPK pathway is repressed. Via the regulation of the cell cycle this metabolic switch impacts on the balance between self-renewal, proliferation and differentiation of the tumor-initiating cells

【 授权许可】

   
2013 Guille et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]The Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70.
• [2]Shah P, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, et al.: The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012, 486:385-399.
• [3]Banerji S, Cibulskis K, Rangel-Escareno K, Brown KK, Carter SL, Frederick AM, et al.: Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012, 486:405-409.
• [4]Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, et al.: Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012, 486:353-360.
• [5]Birnbaum D, Sircoulomb F, Imbert J: A reason why the ERBB2 gene is amplified and not mutated in breast cancer. Cancer Cell Int 2009, 9:5. BioMed Central Full Text
• [6]Hynes N, MacDonald G: ErbB receptors and signaling pathways in cancer. Curr Op Cell Biol 2009, 21:177-184.
• [7]Wu G, Feng X, Lincoln Stein L: A human functional protein interaction network and its application to cancer data analysis. Genome Biol 2010, 11:R53. BioMed Central Full Text
• [8]Oxford KW, Scadden DT: Deconstructing stem cell self-renewal: genetic insights into cell-cycle regulation. Nat Rev Genet 2008, 9:115-127.
• [9]Burdon T, Smith A, Savatier P: Signalling, cell cycle and pluripotency in embryonic stem cells. Trends Cell Biol 2002, 12:432-438.
• [10]Cairns RA, Harris IS, Mak TW: Regulation of cancer metabolism. Nat Rev Cancer 2011, 11:85-95.
• [11]Eijkelenboom A, Burgering BMT: FOXOs: signalling integrators for homeostasis maintenance. Nat Rev Mol Cell Biol 2013, 14:83-97.
• [12]Grunt TW, Mariani GL: Novel approaches for molecular targeted therapy of breast cancer: interfering with PI3K/AKT/mTOR signaling. Curr Cancer Drug Targets 2013, 13:188-204.
• [13]Eisinger F, Sobol H, Birnbaum D: Hypothesis: more mutations to cure cancer? Oncol Rep 1999, 6:1189-1190.